VELTIN
LOE ApproachingNDATOPICALGEL
Approved
Jul 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VELTIN is a fixed-dose combination topical gel containing clindamycin and tretinoin approved for acne treatment. Clindamycin provides antimicrobial activity while tretinoin reduces follicular cohesiveness and increases epithelial cell turnover to extrude comedones. The combination addresses both bacterial and structural components of acne pathogenesis.
LOE Approaching
Product faces approaching loss of exclusivity with moderate competitive pressure (30/100); brand teams should prioritize lifecycle management and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VELTIN offers exposure to dermatology commercial operations and lifecycle management in a maturing product with approaching exclusivity loss. Career advancement requires focus on defensive strategies and potentially transition planning to growth-stage assets.
Brand ManagerProduct Manager
Worked on VELTIN at Almirall? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.